Akoya Biosciences and NeraCare Forge Exclusive Global License Agreement for Immunoprint Test Development in Melanoma Care

Quiver QuantitativeDec 10 08:20 ET

Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...

BenzingaDec 10 08:16 ET

Express News | Akoya Biosciences and Neracare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

ReutersDec 10 08:15 ET

Akoya Biosciences and NeraCare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

GlobeNewswireDec 10 08:15 ET

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

GlobeNewswireDec 9 08:00 ET

Not Many Are Piling Into Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Yet As It Plummets 33%

Simply Wall StDec 6 05:20 ET